全文获取类型
收费全文 | 3436865篇 |
免费 | 251177篇 |
国内免费 | 9231篇 |
专业分类
耳鼻咽喉 | 46497篇 |
儿科学 | 113361篇 |
妇产科学 | 95829篇 |
基础医学 | 482396篇 |
口腔科学 | 94859篇 |
临床医学 | 315086篇 |
内科学 | 674709篇 |
皮肤病学 | 81494篇 |
神经病学 | 282865篇 |
特种医学 | 130907篇 |
外国民族医学 | 1111篇 |
外科学 | 513212篇 |
综合类 | 74106篇 |
现状与发展 | 7篇 |
一般理论 | 1337篇 |
预防医学 | 267915篇 |
眼科学 | 77781篇 |
药学 | 248573篇 |
8篇 | |
中国医学 | 7271篇 |
肿瘤学 | 187949篇 |
出版年
2019年 | 27608篇 |
2018年 | 38669篇 |
2017年 | 29688篇 |
2016年 | 34066篇 |
2015年 | 38383篇 |
2014年 | 53478篇 |
2013年 | 80245篇 |
2012年 | 107065篇 |
2011年 | 113582篇 |
2010年 | 68047篇 |
2009年 | 64944篇 |
2008年 | 105500篇 |
2007年 | 111931篇 |
2006年 | 113753篇 |
2005年 | 109459篇 |
2004年 | 104947篇 |
2003年 | 101182篇 |
2002年 | 97784篇 |
2001年 | 165460篇 |
2000年 | 169516篇 |
1999年 | 142560篇 |
1998年 | 41240篇 |
1997年 | 36728篇 |
1996年 | 36750篇 |
1995年 | 35538篇 |
1994年 | 32447篇 |
1993年 | 30362篇 |
1992年 | 110063篇 |
1991年 | 105658篇 |
1990年 | 102378篇 |
1989年 | 98615篇 |
1988年 | 90461篇 |
1987年 | 88626篇 |
1986年 | 83010篇 |
1985年 | 79429篇 |
1984年 | 59569篇 |
1983年 | 50475篇 |
1982年 | 30187篇 |
1981年 | 26918篇 |
1979年 | 52650篇 |
1978年 | 37270篇 |
1977年 | 31399篇 |
1976年 | 29257篇 |
1975年 | 30850篇 |
1974年 | 36728篇 |
1973年 | 35107篇 |
1972年 | 32997篇 |
1971年 | 30510篇 |
1970年 | 28361篇 |
1969年 | 26998篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
C. Oprea P.J. Szalanski M.V. Gustova I.A. Oprea V. Buzguta 《Applied radiation and isotopes》2009,67(12):2142-2145
R-mode factor analysis was applied to characterize the chemical composition of human teeth investigated by particle induced X-ray emission (PIXE), Rutherford backscattering spectrometry (RBS) and X-ray fluorescence (XRF) techniques. The approach developed in this study enabled the separation between essential mineral teeth components and the pollutants deposited in teeth tissues during the human life. The three independent sources of metals incorporated in human teeth were found. The first source, representing about 43% of the variance of the concentration data, was characterized by pollutant elements of power industry emissions. The second factor was loaded with toxic elements of general urban pollution. The third factor represented the tooth source as it contained mainly large fractions of the mineral components of the tooth tissue as Ca and K. 相似文献
992.
993.
994.
995.
E. González-Guerra M. R. Haro M. C. Fariña L. Martín L. Manzarbeitia L. Requena 《Clinical and experimental dermatology》2009,34(7):800-803
Glomeruloid haemangioma is considered a specific marker of POEMS ( p olyneuropathy, o rganomegaly, e ndocrinopathy, M -protein and s kin changes) syndrome and it is usually but not always associated with multicentric Castleman's disease. We report a 78-year-old man who presented with a single, red-violet soft nodule with superficial telangiectases on the scalp. Histopathologically, the lesion consisted of lobules of coiled aggregated capillaries that involved the lumina of dilated vascular structures, mimicking renal glomeruli. A collagenous stroma separated the capillary lobules, and eosinophilic, periodic-acid–Schiff positive globules of varying sizes and shapes were seen within the cytoplasm of endothelial cells. Immunohistochemical studies with antibodies against IgA and IgG, and against the kappa and lambda light chains of immunoglobulins showed immunoreactivity within the eosinophilic globules. Results of complete blood count, liver, renal and thyroid function tests, fasting blood sugar measurement, serum levels of oestradiol, testosterone, prolactin and cortisol, serum protein electrophoresis, immunoelectrophoresis and immunofixation yielded normal or negative results. No Bence–Jones proteinuria was found in a sample from a 24-h urine collection. To our knowledge, only two cases of glomeruloid haemangioma have been previously reported in patients without POEMS syndrome. We describe the third case of glomeruloid haemangioma in a patient without features of POEMS syndrome. 相似文献
996.
997.
L.J. Mackintosh† M.N.C. de Koning‡ W.G.V. Quint‡ J. ter Schegget‡ I.M. Morgan R.M. Herd† M.S. Campo 《The British journal of dermatology》2009,161(1):56-62
Background Nonmelanoma skin cancer (NMSC) has been linked to cutaneous human papillomaviruses of the genus beta (betaPV).
Objectives We sought to assess the presence of betaPV in NMSC biopsies from a group of Scottish skin cancer patients, both immunocompetent (IC) patients and immunosuppressed (IS) organ transplant recipients.
Methods One hundred and twenty-one paraffin-embedded skin tumours (27 actinic keratosis, 41 intraepidermal carcinoma, 53 squamous cell carcinoma) and 11 normal skin samples were analysed for the presence of betaPV by a polymerase chain reaction–reverse hybridization assay designed to detect the presence of the 25 known betaPV genotypes.
Results In IC patients, betaPV was detected in 30 of 59 (51%) tumours and two of 11 (18%) normal skin samples ( P = 0·046). In IS patients, betaPV was found in 27 of 62 (44%) tumours; no normal skin samples were available for comparison. The most frequently found genotypes were HPV-24, HPV-15 and HPV-38. Of those tumours infected with betaPV, 28 of 57 (49%) were infected with more than one genotype (range 2–8). Tumours from IS patients were from a younger age group (mean age 57·4 years) than IC patients (mean age 73·8 years). Multiple infections were more common in tumours from IC patients (21 of 30; 70%) compared with those from IS patients (seven of 27; 26%) ( P < 0·001). In the IC group, age did not appear to influence the distribution of single and multiple infections whereas in IS patients the proportion of multiple infections to single infections increased with age. There were no multiple infections in normal skin.
Conclusions A wide spectrum of betaPV types was detected in our samples. Further characterization of betaPV in vivo is needed in order to determine the mechanisms by which the virus contributes to cutaneous carcinogenesis. 相似文献
Objectives We sought to assess the presence of betaPV in NMSC biopsies from a group of Scottish skin cancer patients, both immunocompetent (IC) patients and immunosuppressed (IS) organ transplant recipients.
Methods One hundred and twenty-one paraffin-embedded skin tumours (27 actinic keratosis, 41 intraepidermal carcinoma, 53 squamous cell carcinoma) and 11 normal skin samples were analysed for the presence of betaPV by a polymerase chain reaction–reverse hybridization assay designed to detect the presence of the 25 known betaPV genotypes.
Results In IC patients, betaPV was detected in 30 of 59 (51%) tumours and two of 11 (18%) normal skin samples ( P = 0·046). In IS patients, betaPV was found in 27 of 62 (44%) tumours; no normal skin samples were available for comparison. The most frequently found genotypes were HPV-24, HPV-15 and HPV-38. Of those tumours infected with betaPV, 28 of 57 (49%) were infected with more than one genotype (range 2–8). Tumours from IS patients were from a younger age group (mean age 57·4 years) than IC patients (mean age 73·8 years). Multiple infections were more common in tumours from IC patients (21 of 30; 70%) compared with those from IS patients (seven of 27; 26%) ( P < 0·001). In the IC group, age did not appear to influence the distribution of single and multiple infections whereas in IS patients the proportion of multiple infections to single infections increased with age. There were no multiple infections in normal skin.
Conclusions A wide spectrum of betaPV types was detected in our samples. Further characterization of betaPV in vivo is needed in order to determine the mechanisms by which the virus contributes to cutaneous carcinogenesis. 相似文献
998.
Capello E. Vuolo L. Gualandi F. Van Lint M. T. Roccatagliata L. Bonzano L. Pardini M. Uccelli A. Mancardi Gianluigi 《Neurological sciences》2009,30(2):175-175
Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing–remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2–3%, is still the main problem of this powerful therapy. 相似文献
999.
Eric Racine Marie-Josée Dion Christine A. C. Wijman Judy Illes Maarten G. Lansberg 《Neurocritical care》2009,11(3):345-352
Background
Advances in intensive care medicine have increased survival rates of patients with critical neurological conditions. The focus of prognostication for such patients is therefore shifting from predicting chances of survival to meaningful neurological recovery. This study assessed the variability in long-term outcome predictions among physicians and aimed to identify factors that may account for this variability. 相似文献1000.
FDA’S Perspectives on Cardiovascular Devices 总被引:1,自引:0,他引:1
Eric A. Chen Sonna M. Patel-Raman Kathryn O’Callaghan Matthew G. Hillebrenner 《Journal of cardiovascular translational research》2009,2(2):143-146
The Food and Drug Administration (FDA) decision process for approving or clearing medical devices is often determined by a
review of robust clinical data and extensive preclinical testing of the device. The mission statement for the Center for Devices
and Radiological Health (CDRH) is to review the information provided by manufacturers so that it can promote and protect the
health of the public by ensuring the safety and effectiveness of medical devices deemed appropriate for human use (Food, Drug
& Cosmetic Act, §903(b)(1, 2(C)), December 31, 2004; accessed December 17, 2008 ). For high-risk devices, such as ventricular assist devices (VADs), mechanical heart valves, stents, cardiac resynchronization
therapy (CRT) devices, pacemakers, and defibrillators, the determination is based on FDA’s review of extensive preclinical
bench and animal testing followed by use of the device in a clinical trial in humans. These clinical trials allow the manufacturer
to evaluate a device in the intended use population. FDA reviews the data from the clinical trial to determine if the device
performed as predicted and the clinical benefits outweigh the risks. This article reviews the regulatory framework for different
marketing applications related to cardiovascular devices and describes the process of obtaining approval to study a cardiovascular
device in a U.S. clinical trial. 相似文献